Effectiveness and Safety of Additive Therapy and Monotherapy of Glaucoma with Prostamides
Increased intraocular pressure (IOP) is the main risk factor for the development of primary open-angle glaucoma (POAG). Nowadays medicine that reduce IOP remain the main method of treating for POAG. The first-line drugs for POAG are prostaglandin analogues. In Russia, for the first time, it appeared...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ophthalmology Publishing Group
2019-10-01
|
| Series: | Oftalʹmologiâ |
| Subjects: | |
| Online Access: | https://www.ophthalmojournal.com/opht/article/view/1016 |
| _version_ | 1797875472030236672 |
|---|---|
| author | I. R. Gazizova S. R. Zainullina E. B. Martynova |
| author_facet | I. R. Gazizova S. R. Zainullina E. B. Martynova |
| author_sort | I. R. Gazizova |
| collection | DOAJ |
| description | Increased intraocular pressure (IOP) is the main risk factor for the development of primary open-angle glaucoma (POAG). Nowadays medicine that reduce IOP remain the main method of treating for POAG. The first-line drugs for POAG are prostaglandin analogues. In Russia, for the first time, it appeared not in the form of a fixed combination (Bimoptic). In this regard it is very important to evaluate the clinical efficacy and safety of Bimoptic as a monotherapy and additive component in the treatment of patients with POAG. Patients and methods. Patients were divided into 3 groups depending on the treatment. Group I comprised of 34 patients with newly diagnosed glaucoma on monotherapy with bimatoprost 0.03 %. Group II consisted of 30 patients who started taking bimatoprost 0.03 % as a replacement for latanoprost 0.005 % or travoprost 0.004 %. There were 32 patients in group III, who were prescribed bimatoprost 0.03 % as an adjuvant therapy for B-blockers (BB) 0.5 % or carbonic anhydrase inhibitors (ICA) 2 %. Results. According to the results of the clinical study, it was found that instillation of Bimoptik as a monotherapy for newly diagnosed POAG leads to a decrease in IOP level by an average of 32.1 % of the initial level. With the additive tactics of assigning Bimoptik to the BB and / or IKA, the level of IOP goes down by 10.6 % more. If prostaglandin is changed to Bimoptik, the level of IOP decreases by 12.6 % of the prostaglandin-associated values. Also according to acquired data, Bimoptik has a low percentage of adverse reactions, slight hyperemia and discomfort were observed in 5.2 % of cases in all groups. Conclution. Bimoptik effectively reduces the level of IOP in both monotherapy and additive tactics with the least adverse reactions. |
| first_indexed | 2024-04-10T01:48:02Z |
| format | Article |
| id | doaj.art-b033ba4f761d465e8fe0854d109acb6a |
| institution | Directory Open Access Journal |
| issn | 1816-5095 2500-0845 |
| language | Russian |
| last_indexed | 2024-04-10T01:48:02Z |
| publishDate | 2019-10-01 |
| publisher | Ophthalmology Publishing Group |
| record_format | Article |
| series | Oftalʹmologiâ |
| spelling | doaj.art-b033ba4f761d465e8fe0854d109acb6a2023-03-13T09:08:39ZrusOphthalmology Publishing GroupOftalʹmologiâ1816-50952500-08452019-10-0116336637010.18008/1816-5095-2019-3-366-370564Effectiveness and Safety of Additive Therapy and Monotherapy of Glaucoma with ProstamidesI. R. Gazizova0S. R. Zainullina1E. B. Martynova2ФГБНУ «Институт экспериментальной медицины»ГБУ ЗО РБ «Городская клиническая больница № 10»ФГБОУВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова»Increased intraocular pressure (IOP) is the main risk factor for the development of primary open-angle glaucoma (POAG). Nowadays medicine that reduce IOP remain the main method of treating for POAG. The first-line drugs for POAG are prostaglandin analogues. In Russia, for the first time, it appeared not in the form of a fixed combination (Bimoptic). In this regard it is very important to evaluate the clinical efficacy and safety of Bimoptic as a monotherapy and additive component in the treatment of patients with POAG. Patients and methods. Patients were divided into 3 groups depending on the treatment. Group I comprised of 34 patients with newly diagnosed glaucoma on monotherapy with bimatoprost 0.03 %. Group II consisted of 30 patients who started taking bimatoprost 0.03 % as a replacement for latanoprost 0.005 % or travoprost 0.004 %. There were 32 patients in group III, who were prescribed bimatoprost 0.03 % as an adjuvant therapy for B-blockers (BB) 0.5 % or carbonic anhydrase inhibitors (ICA) 2 %. Results. According to the results of the clinical study, it was found that instillation of Bimoptik as a monotherapy for newly diagnosed POAG leads to a decrease in IOP level by an average of 32.1 % of the initial level. With the additive tactics of assigning Bimoptik to the BB and / or IKA, the level of IOP goes down by 10.6 % more. If prostaglandin is changed to Bimoptik, the level of IOP decreases by 12.6 % of the prostaglandin-associated values. Also according to acquired data, Bimoptik has a low percentage of adverse reactions, slight hyperemia and discomfort were observed in 5.2 % of cases in all groups. Conclution. Bimoptik effectively reduces the level of IOP in both monotherapy and additive tactics with the least adverse reactions.https://www.ophthalmojournal.com/opht/article/view/1016первичная открытоугольная глаукомабиматопростпростамидымонотерапия простамидамиаддитивная терапия простамидами |
| spellingShingle | I. R. Gazizova S. R. Zainullina E. B. Martynova Effectiveness and Safety of Additive Therapy and Monotherapy of Glaucoma with Prostamides Oftalʹmologiâ первичная открытоугольная глаукома биматопрост простамиды монотерапия простамидами аддитивная терапия простамидами |
| title | Effectiveness and Safety of Additive Therapy and Monotherapy of Glaucoma with Prostamides |
| title_full | Effectiveness and Safety of Additive Therapy and Monotherapy of Glaucoma with Prostamides |
| title_fullStr | Effectiveness and Safety of Additive Therapy and Monotherapy of Glaucoma with Prostamides |
| title_full_unstemmed | Effectiveness and Safety of Additive Therapy and Monotherapy of Glaucoma with Prostamides |
| title_short | Effectiveness and Safety of Additive Therapy and Monotherapy of Glaucoma with Prostamides |
| title_sort | effectiveness and safety of additive therapy and monotherapy of glaucoma with prostamides |
| topic | первичная открытоугольная глаукома биматопрост простамиды монотерапия простамидами аддитивная терапия простамидами |
| url | https://www.ophthalmojournal.com/opht/article/view/1016 |
| work_keys_str_mv | AT irgazizova effectivenessandsafetyofadditivetherapyandmonotherapyofglaucomawithprostamides AT srzainullina effectivenessandsafetyofadditivetherapyandmonotherapyofglaucomawithprostamides AT ebmartynova effectivenessandsafetyofadditivetherapyandmonotherapyofglaucomawithprostamides |